The abstract is read at the publisher; the summary is JClub's.
In colorectal cancer, WIP1/PPM1D is upregulated in tumor tissues and its genetic or pharmacological inhibition robustly suppresses tumor growth by remodeling the immune microenvironment.
- Why it matters: Immune checkpoint inhibitors have limited efficacy in CRC because the tumor microenvironment is immunosuppressive, and innate-immune activation strategies are insufficiently explored.
- What they did: The study used genetic and pharmacological WIP1 inhibition to assess tumor growth and immune infiltration, then tested mechanism via effects on type I IFN signaling, dsDNA accumulation, and TBK1 phosphorylation at Ser172.
- The result: WIP1 inhibition suppressed cGAS-STING-TBK1 signaling and, when combined with a STING agonist, synergistically enhanced anti-tumor efficacy by amplifying IFNβ production and further potentiated anti-PD-1 immunotherapy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.